Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Inc. (Nasdaq: TENX) (“” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback